BioSpace News Archive

Horizon Therapeutics plc announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinical transverse myelitis lesions in people with NMOSD.

Rakuten Medical, Inc. announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting held from June 24 to 27.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

MDxHealth SA, a commercial-stage precision diagnostics company, held an extraordinary general shareholders’ meeting.

NeuBase Therapeutics, Inc. announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 578,697 of its shares of common stock at a purchase price of $2.57 per share and associated unregistered warrants and concurrent private placement of an aggregate of 1,366,829 of its shares of common stock, at the same purchase price of $2.57 per share and associated unregistered warrants.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 23 new employees.

NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that the NLS Shareholders approved all of the Board of Directors’ proposals for the 2023 Annual General Meeting that took place in Zürich, Switzerland.

Ionis Pharmaceuticals announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® in infants and toddlers living with spinal muscular atrophy.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.